A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Polatuzumab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Obinutuzumab; Prednisolone; Prednisone; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Acronyms Pola-R-Chp
  • Sponsors Genentech
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 1 Dec 2018 to 27 Dec 2018.
    • 10 Jul 2017 Planned primary completion date changed from 1 Dec 2018 to 27 Dec 2018.
    • 25 Jun 2017 Updated safety and efficacy results (n=45; data cut off 4 November 2016) for the phase II dose, presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top